Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: The French compassionate experience

Bone Marrow Transplantation

Volumn 46, Issue 7, 2011, Pages 936-942

  Lapierre, V ^a   Rossi, J F ^b,c   Heshmati, F ^d   Azar, N ^e   Vekhof, A ^e   Makowski, C ^f   Moreau, P ^g   Caillot, D ^h   Auperin, A ^a   Chabannon, C ^c,i  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d Institut Cochin   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h DIJON UNIVERSITY HOSPITAL   (France)

ⁱ INSTITUT PAOLI CALMETTES   (France)

Author keywords

clinical transplantation; G CSF; high dose chemotherapy; SCF; stem cell mobilization

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR;

ADULT; ARTHRALGIA; ARTICLE; AUTOTRANSPLANTATION; BLOOD SAMPLING; BONE PAIN; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPILEPSY; ERYTHEMA; FACIAL NERVE PARALYSIS; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN TISSUE; HYPOTENSION; INTERSTITIAL PNEUMONIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MOUTH EDEMA; MYELOMA; PRIORITY JOURNAL; PRURITUS; SYNCOPE; VOMITING; WALKING DIFFICULTY;

ADOLESCENT; ADULT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASMS; RECOMBINANT PROTEINS; STEM CELL FACTOR; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 79960186271     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.231     Document Type: Article

References (37)

1. Gratwohl A, Baldomero H, Frauendorfer K, Niederwieser D. Why are there regional differences in stem cell transplantation activity? An EBMT analysis. Bone Marrow Transplant 2008; 42 (Suppl 1): S7-S10.
2. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Frauendorfer K, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
3. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831. (Pubitemid 24264657)
4. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-607. (Pubitemid 27172186)
5. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
6. Benboubker L, Watier H, Carion A, Georget MT, Desbois I, Colombat P, et al. Association between the SDF1-30A allele and high levels of CD34(+) progenitor cells mobilized into peripheral blood in humans. Br J Haematol 2001; 113: 247-250. (Pubitemid 32423330)
7. Bogunia-Kubik K, Gieryng A, Dlubek D, Lange A. The CXCL12-30A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantation. Bone Marrow Transplant 2009; 44: 273-278.
8. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092-2100.
9. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkins lymphoma, Hodgkins disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338. (Pubitemid 351330727)
10. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909-917.
11. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
12. Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-68.
13. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55: 1-96.
14. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183: 2681-2686. (Pubitemid 26192378)
15. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkins disease or non-Hodgkins lymphoma. Bone Marrow Transplant 2000; 26: 471-481.
16. Chin-Yee IH, Keeney M, Stewart AK, Belch A, Bence-Buckler I, Couban S, et al. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets. Bone Marrow Transplant 2002; 30: 851-860. (Pubitemid 36097473)
17. To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM, et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003; 31: 371-378. (Pubitemid 36410683)
18. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005; 36: 389-396. (Pubitemid 43115025)
19. Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA, et al. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia 2008; 23: 305-312.
20. da Silva MG, Pimentel P, Carvalhais A, Barbosa I, Machado A, Campilho F, et al. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. Bone Marrow Transplant 2004; 34: 683-691. (Pubitemid 39406052)
21. Panterne B, Sabatini C, Huyghe G, Maquin C, Mouillot L, TIissier MH. External quality controls of cellular products: the French experience. Cytotherapy 2006; 8(Suppl 1): 176.
22. Pusic I, DiPersio JF. The use of growth factors in hematopoietic stem cell transplantation. Curr Pharm Des 2008; 14: 1950-1961.
23. MacVittie TJ, Farese AM, Davis TA, Lind LB, McKearn JP. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated nonhuman primates. Exp Hematol 1999; 27: 1557-1568. (Pubitemid 29458431)
24. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008; 8: 332.
25. Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol 2009; 9: 2.
26. Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY, et al. Randomized, controlled, doserange study of Ro 25-8315 given before and after a highdose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. J Clin Oncol 2002; 20: 24-36. (Pubitemid 34032592)
27. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, et al. A single dose of 6 or 12mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46: 180-185. (Pubitemid 43381751)
28. Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007; 13: 838-843. (Pubitemid 46902439)
29. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287-3295. (Pubitemid 38525653)
30. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-2730. (Pubitemid 37248839)
31. Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998.
32. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874. (Pubitemid 41208607)
33. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkins lymphoma. J Clin Oncol 2004; 22: 1095-1102. (Pubitemid 41095043)
34. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
35. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, et al. Treatment with plerixafor in non-Hodgkins lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249-256.
36. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and highdose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904-1912.
37. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729-1735.